Showing 7 posts of 7 posts found.


FDA approves Exelixis’ cancer drug Cabometyx

January 25, 2021
Sales and Marketing Cancer, Exelixis

The FDA has approved Exelixis’ Cabometyx (cabozantinib) for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in …


Phase 3 kidney cancer trial of Bristol Myers Squibb’s Opdivo and Exelixis’ Cabometyx meets primary endpoint

April 21, 2020
Manufacturing and Production BMS, Bristol-Myers Squibb, Exelixis, bristol myers squibb

Bristol Myers Squibb and Exelixis have announced that the Phase 3 trial investigating the combination of Opdivo (nivolumab) and Cabometyx …


Roche’s immunotherapy lucky streak ends with deaths in trial

April 13, 2018
Medical Communications, Research and Development Exelixis, Roche, biotech, drugs, pharma, pharmaceutical, tecentriq

Roche’s Tecentriq had begun to show signs of reviving its hopes in the competitive PD-1/L1 market, succeeding in two Phase …


Ipsen ends P3 trial on liver cancer early due to strong data

January 18, 2018
Research and Development Cabometyx, Exelixis, biotech, drugs, ipsen, pharma, pharmaceutical

Ipsen and Exelixis, partners in developing Cabometyx (cabozantinib), have revealed that they have cut short a Phase 3 trial into …


Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial

October 11, 2016
Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma

Phase II results presented by genomics-based discovery company  Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …


Exelixis signs $200 million licensing deal for cancer drug

March 1, 2016
Research and Development, Sales and Marketing Cancer, Cometriq, Exelixis, ipsen

Exelixis has signed a licensing agreement with French biotech firm Ipsen for its cancer drug Cometriq (cabozantinib) for an upfront …


Regulus names Stelios Papadopoulos as chairman

June 12, 2013
Manufacturing and Production, Research and Development, Sales and Marketing Alnylam, Exelixis, Regulas

Biopharma firm Regulas Therapeutics has named Stelios Papadopoulos chairman of its Board of directors.  Papadopoulos assumes the role from John …

Latest content